by John Conrad | Aug 2, 2024 | NewsBrief
On August 1, 2024, AbbVie completed its acquisition of Cerevel Therapeutics, marking a significant milestone in the quest to improve treatments for millions of people living with neurological and psychiatric conditions. This union brings together two companies...
by John Conrad | Jun 28, 2024 | NewsBrief
AbbVie continues to bolster its immunology portfolio beyond Humira, announcing on Thursday its acquisition of early-stage biotech Celsius Therapeutics for $250 million in cash. This move aims to strengthen AbbVie’s longer-term prospects in inflammatory bowel...
by John Conrad | Jun 27, 2024 | NewsBrief
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Epkinly (epcoritamab-bysp), a joint development by AbbVie and Genmab, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL). This approval specifically...
by John Conrad | Jun 13, 2024 | NewsBrief
Inflammatory Bowel Disease (IBD) affects millions of people worldwide, causing chronic inflammation in the digestive tract and leading to debilitating symptoms. Current therapies often fail to provide adequate relief for many patients, highlighting the urgent need for...
by John Conrad | Jun 10, 2024 | NewsBrief
In a significant development for patients with vanishing white matter (VWM) disease, AbbVie and Alphabet’s Calico announced on Friday that their investigational eIF2B activator, fosigotifator, has been selected to participate in the FDA’s new Support for...
